Neo Ivy Capital Management Increases Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Neo Ivy Capital Management grew its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 145.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 166,734 shares of the company's stock after acquiring an additional 98,798 shares during the period. Hims & Hers Health comprises about 0.8% of Neo Ivy Capital Management's investment portfolio, making the stock its 21st biggest position. Neo Ivy Capital Management owned about 0.08% of Hims & Hers Health worth $4,031,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in HIMS. Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter worth about $28,000. Raleigh Capital Management Inc. lifted its position in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 1,100 shares in the last quarter. Blume Capital Management Inc. lifted its position in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 600 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after buying an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter worth about $38,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Hims & Hers Health news, CEO Andrew Dudum sold 47,534 shares of the company's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $58.25, for a total transaction of $2,768,855.50. Following the completion of the sale, the chief executive officer now owns 285,194 shares in the company, valued at $16,612,550.50. This represents a 14.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Patrick Harrison Carroll sold 23,287 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $34.31, for a total value of $798,976.97. Following the sale, the insider now owns 209,661 shares of the company's stock, valued at approximately $7,193,468.91. This represents a 10.00% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 618,936 shares of company stock worth $25,182,692 over the last 90 days. Company insiders own 13.71% of the company's stock.

Hims & Hers Health Stock Down 7.6%

Shares of NYSE:HIMS opened at $53.58 on Friday. Hims & Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98. The stock has a market cap of $11.99 billion, a P/E ratio of 121.78 and a beta of 1.84. The business's 50 day moving average is $37.48 and its 200 day moving average is $34.77.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health's revenue was up 110.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.05 earnings per share. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on HIMS. Wall Street Zen upgraded Hims & Hers Health from a "hold" rating to a "buy" rating in a research report on Thursday. Leerink Partners boosted their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Bank of America boosted their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Finally, Needham & Company LLC reissued a "buy" rating and set a $61.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $37.67.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.